Media Release
FOR IMMEDIATE RELEASE
IMV Inc. to Present at Upcoming Investor Conferences
Dartmouth, Nova Scotia, May 14, 2019 - IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that IMV Chief Executive Officer Frederic Ors will present at the following investor conferences in May:
RBC Capital Markets Global Healthcare Conference
-
Date: Tuesday, May 21, 2019
-
Time: 1:35 p.m. ET
-
Location: The InterContinental New York Barclay Hotel, New York, NY
National Bank Financials’ 9th Annual Quebec Conference
-
Date: Wednesday, May 29, 2019
-
Time: 9:50 a.m. ET
-
Location: Museum Room, Shangri-la Hotel, Toronto, Ontario
China Bio-Partnering Forum
-
Date: Thursday, May 30, 2019
-
Time: 1:40 P.M. CT
-
Location: Renaissance Schaumburg Convention Center Hotel, Chicago, IL
A copy of each meeting’s presentation will be available in the events and presentations section of IMV’s website. A live webcast of IMV’s presentation at the RBC Capital Markets conference will also be available and archived for 90 days on the events and presentations webpage.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Connect at www.imv-inc.com.